19 min listen
NTRK Fusions
FromModPath Chat
ratings:
Length:
23 minutes
Released:
Dec 7, 2021
Format:
Podcast episode
Description
Identification of molecular alterations in NTRK 1-3 has become increasingly important with the emergence of histology-agnostic, US Food and Drug Administration-approved, effective inhibitors. The host discusses with Dr. Jaclyn Hechtman, director of clinical diagnostic development at Neogenomics, her practical insights on how testing for NTRK fusion can best be implemented and communicated within the multidisciplinary healthcare team. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Released:
Dec 7, 2021
Format:
Podcast episode
Titles in the series (58)
COVID-19 pulmonary pathology in cross Atlantic pandemic epicenters: A discussion with Dr. Borczuk of New York Presbyterian Hospital- Weill Cornell Medicine on his team findings in sixty eight COVID-19 autopsies, performed early on during the pandemic, at 3 institutions in heavily hit areas (2 USA, 1 Italy). by ModPath Chat